DUBLIN /PRNewswire/ --

The "Wearable Injectors Market by Type (On-Body and Off-Body injectors (Infusion Pump Devices)), Therapy (Immuno-oncology, Diabetes, Cardiovascular Diseases, Parkinson's Disease, Thalassemia, Primary Immunodeficiency Disease) - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.

The global wearable injectors market is projected to reach USD 9.41 billion by 2023 from USD 5.57 billion in 2018, at a CAGR of 11.1% during the forecast period. 

The growth of this market is primarily driven by the growing prevalence of chronic diseases (such as cancer, diabetes, and CVD); the favorable reimbursement scenario in major markets; and technological advancements in injector devices. However, the preference for alternative drug delivery modes and a poor reimbursement structure in developing countries is expected to limit the adoption of wearable injector devices to a certain extent.

The market is segmented on the basis of type, therapy, and region. Based on type, the market is segmented into on-body and off-body injectors. The on-body wearable injectors segment is expected to account for the larger market share in 2018, while the off-body injectors segment is projected to witness the highest growth rate during the forecast period. The drawbacks associated with on-body wearable injectors, such as painful removal, skin sensitivity issues and irritation, and adhesive fitting issues have resulted in the increased adoption of off-body injectors.

Based on therapy, the global wearable injectors market is segmented into immune-oncology, diabetes, cardiovascular diseases, and other therapies (such as Parkinson's disease, thalassemia, and primary immunodeficiency disease). The immuno-oncology segment is expected to account for the largest share of the market in 2018. The large share of this segment can be attributed to the high prevalence of cancer across the globe.

By region, the global market is segmented into North America, Europe, Asia Pacific, and the RoW. The North American region is expected to account for the largest market share in 2018. The large share of this region can be attributed to the rising prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases and favorable reimbursement scenario in this region.

The global wearable injectors market is dominated by Amgen (US), Medtronic (Ireland), Insulet Corporation (US), Tandem Diabetes Care (US), United Therapeutic Corporation (US), and Valeritas (US). 

These players adopted growth strategies such as product launches, product approvals, agreements, and expansions to maintain and enhance their positions in the market. 

Other prominent players in the market include Ypsomed (Switzerland), Becton, Dickinson and Company (US), SteadyMed Therapeutics (US), Enable Injections (US), Sensile Medicals (Switzerland), and Bespak (UK).

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights
4.1 Wearable Injectors Market: Overview
4.2 Global Market, By Type, 2018 vs 2023
4.3 Geographic Analysis: Global Market, By Therapy
4.4 Geographic Snapshot: Global Market

5 Wearable Injectors Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Growing Prevalence of Chronic Diseases
5.2.1.2 Favorable Reimbursement Scenario in Major Markets
5.2.1.3 Technological Advancements and Design Development
5.2.2 Restraints
5.2.2.1 Preference for Alternative Drug Delivery Modes
5.2.3 Opportunities
5.2.3.1 Increasing Demand for Biologics and MABS
5.2.4 Challenges
5.2.4.1 Unfavorable Reimbursement Structure in Developing Countries

6 Wearable Injectors Market By Type
6.1 Introduction
6.2 On-Body Injectors
6.3 Off-Body Injectors

7 Wearable Injectors Market By Therapy
7.1 Introduction
7.2 Immuno-Oncology
7.3 Diabetes
7.4 Cardiovascular Diseases
7.5 Other Therapies

8 Wearable Injectors Market By Region
8.1 Introduction
8.2 North America
8.2.1 US
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 RoAPAC
8.5 Rest of the World

9 Competitive Landscape
9.1 Overview
9.2 Market Share Analysis
9.3 Market Share Analysis, By Therapy
9.3.1 Immuno-Oncology
9.3.2 Amgen
9.3.3 Diabetes
9.3.4 Medtronic
9.3.5 Insulet Corporation
9.3.6 Cardiovascular Diseases
9.3.7 United Therapeutics
9.4 Competitive Scenario
9.4.1 Product Launches and Approvals
9.4.2 Expansions
9.4.3 Agreements, Collaborations, and Partnerships

10 Company Profiles
10.1 Amgen
10.2 Medtronic PLC
10.3 Insulet Corporation
10.4 Ypsomed
10.5 Becton, Dickinson and Company
10.6 Tandem Diabetes Care, Inc.
10.7 United Therapeutics Corporation
10.8 Valeritas, Inc.
10.9 Enable Injections
10.10 Steadymed Therapeutics
10.11 Sensile Medical (A Part of Gerresheimer)

For more information about this report visit https://www.researchandmarkets.com/research/dgg4rn/wearable?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Research and Markets 
Laura Wood, Senior Manager 
press@researchandmarkets.com 

For E.S.T Office Hours Call +1-917-300-0470 
For U.S./CAN Toll Free Call +1-800-526-8630 
For GMT Office Hours Call +353-1-416-8900 

U.S. Fax: 646-607-1907 
Fax (outside U.S.): +353-1-481-1716